At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial ...

Perjeta (pertuzumab) is approved for use in combination with Herceptin (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body ...

Perjeta (pertuzumab) is a prescription medicine approved for use in combination with Herceptin (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to ...

The combination of Herceptin, Perjeta, and endocrine therapy without chemotherapy showed promising results in patients with HR+/HER2+ metastatic breast cancer. Adding Kisqali to the treatment regimen ...

Herceptin wasn’t used with Perjeta (pertuzumab) in Herceptin’s studies. But this combination was examined in Perjeta’s studies , which included people whose conditions were treated with ...

The treatment combination of Perjeta (pertuzumab) plus Herceptin (trastuzumab) alone without chemotherapy during first-line treatment, followed by Kadcyla (trastuzumab plus emtansine) as second-line ...

At a three-year follow-up, 94.1% of those receiving both Perjeta and Herceptin hadn’t developed an invasive form of the HER2-positive disease, compared with 93.2% of women taking Herceptin solo ...

Roche's Perjeta, Herceptin and chemotherapy regimen cut the risk of death by 17% in patients with early-stage HER2-positive breast cancer over 10 years.

The panel will review a 417-woman study comparing Perjeta in different combinations against older breast cancer treatments. When Perjeta was combined with Herceptin, another Genentech drug, and ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin ...

There is no control arm in this trial, but one can use the CLEOPATRA trial as a benchmark where the median PFS for Perjeta in combination with Herceptin and docetaxel was 18.5 months compared to ...

Genentech, a member of the Roche Group, today announced new data from the Phase III FeDeriCa study which showed the investigational fixed-dose combination of Perjeta ® and Herceptin ® with ...